These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

865 related items for PubMed ID: 27022038

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Ethical imperatives of timely access to orphan drugs: is possible to reconcile economic incentives and patients' health needs?
    Rodriguez-Monguio R, Spargo T, Seoane-Vazquez E.
    Orphanet J Rare Dis; 2017 Jan 05; 12(1):1. PubMed ID: 28057032
    [Abstract] [Full Text] [Related]

  • 3. Novel treatments for rare rheumatologic disorders: analysis of the impact of 30 years of the US orphan drug act.
    Lutz T, Lampert A, Hoffmann GF, Ries M.
    Orphanet J Rare Dis; 2016 May 12; 11(1):60. PubMed ID: 27176041
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. What the Orphan Drug Act has done lately for children with rare diseases: a 10-year analysis.
    Thorat C, Xu K, Freeman SN, Bonnel RA, Joseph F, Phillips MI, Imoisili MA.
    Pediatrics; 2012 Mar 12; 129(3):516-21. PubMed ID: 22371464
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Orphan Drugs and Their Impact on Pharmaceutical Development.
    Attwood MM, Rask-Andersen M, Schiöth HB.
    Trends Pharmacol Sci; 2018 Jun 12; 39(6):525-535. PubMed ID: 29779531
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Rare cancer trial design: lessons from FDA approvals.
    Gaddipati H, Liu K, Pariser A, Pazdur R.
    Clin Cancer Res; 2012 Oct 01; 18(19):5172-8. PubMed ID: 22718862
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Are products with an orphan designation for oncology indications different from products for other rare indications? A retrospective analysis of European orphan designations granted between 2002-2012.
    Pauwels K, Huys I, Casteels M, Larsson K, Voltz C, Penttila K, Morel T, Simoens S.
    Orphanet J Rare Dis; 2017 Feb 16; 12(1):36. PubMed ID: 28209180
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The Orphan Drug Act: Restoring the Mission to Rare Diseases.
    Daniel MG, Pawlik TM, Fader AN, Esnaola NF, Makary MA.
    Am J Clin Oncol; 2016 Apr 16; 39(2):210-3. PubMed ID: 26580246
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. FDA orphan products clinical trial grants: assessment of outcomes and impact on rare disease product development.
    Miller KL, Mueller C, Liu G, Miller Needleman KI, Maynard J.
    Orphanet J Rare Dis; 2020 Sep 03; 15(1):234. PubMed ID: 32883327
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 44.